Cardiac Cachexia: A Well-Known but Challenging Complication of Heart Failure.
Helena KrysztofiakMarta WleklikJacek MigajMagdalena DudekIzabella UchmanowiczMagdalena LisiakGrzegorz KubielasEwa Straburzyńska-MigajMaciej LesiakMarta Kaluzna-OleksyPublished in: Clinical interventions in aging (2020)
Heart failure (HF) is a common complication of various cardiac diseases, and its incidence constantly increases. This is caused mainly by aging of populations and improvement in the treatment of coronary artery disease. As HF patients age, they tend to develop comorbidities, creating new problems for health-care professionals. Sarcopenia, defined as the loss of muscle mass and function, and cachexia, defined as weight loss due to an underlying illness, are muscle wasting disorders of particular relevance in the heart failure population, but they go mostly unrecognized. The coexistence of chronic HF and metabolic disorders facilitates the development of cachexia. Cachexia, in turn, significantly worsens a patient's prognosis and quality of life. The mechanisms underlying cachexia have not been explained yet and require further research. Understanding its background is crucial in the development of treatment strategies to prevent and treat tissue wasting. There are currently no specific European guidelines or recommended therapy for cachexia treatment in HF ("cardiac cachexia").
Keyphrases
- heart failure
- acute heart failure
- left ventricular
- coronary artery disease
- healthcare
- weight loss
- end stage renal disease
- mental health
- ejection fraction
- atrial fibrillation
- newly diagnosed
- bariatric surgery
- chronic kidney disease
- cardiac resynchronization therapy
- skeletal muscle
- prognostic factors
- case report
- type diabetes
- body mass index
- insulin resistance
- combination therapy
- gastric bypass
- patient reported